The latest price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) was reported by Wells Fargo on March 12, 2026. The analyst firm set a price target for $143.00 expecting RYTM to rise to within 12 months (a possible 62.91% upside). 48 analyst firms have reported ratings in the last year.

The latest analyst rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) was provided by Wells Fargo, and Rhythm Pharmaceuticals maintained their overweight rating.

The last upgrade for Rhythm Pharmaceuticals Inc happened on December 19, 2023 when Morgan Stanley raised their price target to $55. Morgan Stanley previously had an equal-weight for Rhythm Pharmaceuticals Inc.

The last downgrade for Rhythm Pharmaceuticals Inc happened on May 8, 2024 when B of A Securities changed their price target from $49 to $42 for Rhythm Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rhythm Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rhythm Pharmaceuticals was filed on March 12, 2026 so you should expect the next rating to be made available sometime around March 12, 2027.

While ratings are subjective and will change, the latest Rhythm Pharmaceuticals (RYTM) rating was a maintained with a price target of $136.00 to $143.00. The current price Rhythm Pharmaceuticals (RYTM) is trading at is $87.78, which is out of the analyst’s predicted range.